(Q33650699)

28 July 2017

1 reference

title

Practical considerations of the pharmacology of angiotensin receptor blockers (English)

1 reference

28 July 2017

1 reference

McConnaughey MM

1

1 reference

28 July 2017

McConnaughey JS

series ordinal

2

1 reference

28 July 2017

Ingenito AJ

series ordinal

3

1 reference

28 July 2017

publication date

1 June 1999

1 reference

The Journal of Clinical Pharmacology

28 July 2017

published in

1 reference

28 July 2017

volume

39

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

547-559

1 reference

Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system.

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Interactions between angiotensin II and the sympathetic nervous system in the the long-term control of arterial pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Angiotensin II stimulation in vitro induces hypertrophy of normal and postinfarcted ventricular myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Tonin, angiotensin II system. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Chymase-dependent angiotensin II forming systems in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Quantitative studies of antagonists for 5-hydroxytryptamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Classification of angiotensin receptors in rat isolated uterus, portal vein, and aorta using a slowly dissociating antagonist [Sar1,Ile8]ANG II for receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Molecular mechanisms of angiotensin II (AT1a) receptor endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Identification of angiotensin II receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Preliminary biochemical characterization of two angiotensin II receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Angiotensin receptors and their antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Inositol phosphates turnover, cytosolic Ca++ and pH: putative signals for the control of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

The emerging concept of vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

The role of angiotensin receptors in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Angiotensin receptors and their therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Receptors and their classification: focus on angiotensin II and the AT2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Angiotensin receptors in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Regulation of blood pressure by the type 1A angiotensin II receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Angiotensin converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Anti-ischaemic effects of converting enzyme inhibitors: underlying mechanisms and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Clinical safety and tolerability of losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Reversible ageusia associated with losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Reversible acute renal failure induced by losartan in a renal transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

The effects of angiotensin II and specific angiotensin receptor blockers on embryonic cardiac development and looping patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Losartan: first of a new class of angiotensin antagonists for the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Vascular remodeling: the role of angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Effects of chronic hypertension and its reversal on arteries and arterioles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

ACE inhibitors in heart failure: prospects and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Emerging concepts: angiotensin-converting enzyme inhibition in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Angiotensin-Converting Enzyme Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Effects of losartan and enalapril on small artery structure in hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Renoprotection and renin-angiotensin system blockade in diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Antihypertensive therapy. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Importance of angiotensin-converting enzyme inhibitors in myocardial infarction and congestive heart failure: implications for clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Safety, tolerability, and neurohormonal changes of the combination captopril plus losartan in the early postinfarction period: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Induction of the proto-oncogene c-jun by angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

The renin-angiotensin system and vascular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

Experience with angiotensin II antagonists in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008155

10.1177/00912709922008155

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference